Genitourinary Cancers | Tumor

What Patients With Kidney Cancer Need to Know From ASCO GU

March 30th 2025, 2:00pm

Article

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Top 3 Takeaways From ASCO GU 2025

March 25th 2025, 8:16pm

Video

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

Investigating Quality of Life and Treatment Adherence in Kidney Cancer

March 18th 2025, 7:00pm

Video

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.

Biomarkers, Genetic Testing and More Make Way in GU Cancers

March 5th 2025, 2:00pm

Article

Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies across kidney, bladder and prostate cancers.

Better Understanding Genetic Mutations Influence in Cancer Care

March 4th 2025, 8:02pm

Video

Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.

An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium

February 28th 2025, 5:00pm

Video

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.

There is a Growing Need For Genetic Testing and Precision Medicine in GU Cancers

February 28th 2025, 2:00pm

Article

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

Personalized Medicine Makes Strides Across the GU Oncology Treatment Space

February 22nd 2025, 3:00pm

Video

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

GAP Regimen May Not Improve Survival in Biliary Tract Cancer Subset

February 17th 2025, 2:00pm

Article

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT

February 13th 2025, 10:00pm

Article

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.

x